NCT05610956
Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis
Recruiting · Early Phase 1 · Tanta University · registry updated 2025-07-16
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
•This study will be a randomized, controlled, parallel study. .To demonstrate the efficacy of empagliflozin and clinical improvement in patients of mild to moderate UC using the Montreal classification of severity of ulcerative colitis.
Inclusion
- Patients with mild to moderate UC are diagnosed by history, clinical signs according to the Montreal classification of severity of ulcerative colitis and( Endoscopy, and biopsy) to establish the chronicity of inflammation and to exclude other causes of colitis.
Exclusion
- Other inflammatory bowel diseases (CD).
- History of serious hypersensitivity to empagliflozin or any component of the formulation.
- Patients on dialysis.
- Severe renal impairment (eGFR \<20 ml/minute/1.73m2) .
- Chronic urinary tract infection.
- Chronic genital infection.